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Abstract
Aims/hypothesis An inverse association has consistently been
shown between diabetes and prostate cancer incidence. We
investigated whether lower prostate cancer incidence among
men with diabetes is attributable to lower detection due to
prostate cancer screening patterns.
Methods We studied a population-based historical cohort of
1,034,074 Israeli men aged 21–90 years, without a previous
history of cancer. The cohort was followed-up from 2002 to
2012, according to diabetes morbidity, for frequency of
prostate-specific antigen (PSA) testing, mean PSA values
and detection of prostate cancer, after adjustment for age, eth-
nic origin, socioeconomic status and PSA testing.
Results In January 2002, 74,756 men had prevalent diabetes.
During the 11 year follow-up, 765,483 (74%) remained
diabetes-free and 193,835 developed diabetes. Approximately
10% more PSA screening was performed in men with than
without diabetes, but the rate of PSA positivity (>4 μg/l) was
20% lower in men with diabetes. PSA values were already
significantly lower in men who developed diabetes than in
those who did not, 3 years before diabetes diagnosis. Reduced
prostate cancer risk was observed among men with incident
diabetes only for low–moderate grade tumours (Gleason score
2–6: adjusted HR 0.83; 95%CI 0.77, 0.89). No association was
observed for high-grade tumours (Gleason score 7–10: HR
0.99; 95% CI 0.88, 1.11).
Conclusions/interpretation Our findings suggest that diabetes
comorbidity is a factor to be considered in prostate cancer
screening strategies, and specifically in the interpretation of
PSA levels. Furthermore, our demonstration of reduced inci-
dence of low–moderate grade but not high-grade prostate can-
cer tumours among men with diabetes supports the possibility
that low PSA levels, rather than lower tumour risk, explains
the observed reduced incidence of prostate cancer in men with
diabetes.
Trial registration: ClinicalTrials.gov NCT02072902
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Many studies have shown an inverse association between
diabetes and prostate cancer incidence; recent publications
include two large meta-analyses of case–control and cohort
studies [1], the European Prospective Investigation into
Cancer and Nutrition (EPIC) study [2], and nationwide studies
from Sweden [3] and Australia [4]. Similar data have been
reported in Israel [5–7]. A number of US investigations have
reported that the strength of this negative association increases
with increased duration of diabetes [8–10], while others have
shown it to remain constant with diabetes duration [11]. By
contrast, studies in Chinese populations have shown positive
associations between diabetes and prostate cancer [12].
Only a few investigations of the association between dia-
betes and prostate cancer have stratified by grade of prostate
cancer. The EPIC study did not find evidence that the inverse
association differed by disease grade [2]; however, grade was
available for fewer than half of the cases. Two Japanese stud-
ies [13, 14], a Korean study [15], a Swedish study [16] and a
US retrospective study [17] reported positive associations be-
tween diabetes and aggressive prostate cancer. A prospective
US study [18] with 9 years of follow-up showed that diabetes
was inversely associated with early stage prostate cancer, but
not associated with aggressive prostate cancer. A systematic
review identified four studies that analysed the association
between diabetes and prostate cancer according to grade. A
meta-analysis of these studies revealed an inverse association
for both low-grade and high-grade cancer, which was stronger
for the former [19].
Studies conducted in the USA have reported increased
screening rates for prostate cancer following diabetes diagno-
sis [20]. Cross-sectional studies conducted in Japan [21] and
Germany [22] showed lower prostate-specific antigen (PSA)
levels in men with diabetes than in men without the disease. In
addition, a US prospective cohort study of randomly selected
men reported less annual changes in PSA in men with than
without diabetes [23]. Longer diabetes duration [24] and more
severe diabetes [22] were found to be associated with lower
PSA levels. However, none of the above studies investigated
whether diabetes-specific patterns of surveillance or of PSA
levels may contribute to an inverse association between dia-
betes and prostate cancer incidence.
We investigated whether the observed lower incidence of
prostate cancer among men with diabetes may be a conse-
quence of prostate cancer screening. To this end, we estimated
HRs for prostate cancer among men with diabetes, according
to grade of prostate cancer, and compared rates of prostate
cancer screening and PSA level distributions among men with
and without diabetes.
Methods
The study is based on electronic records from the largest
health maintenance organisation in Israel, Clalit Health
Services, which insures and provides healthcare to 53%
(4.3 million) of the nation’s population. All men aged 21 to
89 years on 1 January 2002 (the date of study entry), without a
previous history of cancer, were included in a closed historical
cohort that was followed until 31 December 2012 for the
incidence of diabetes. All men were followed-up for prostate
cancer incidence, which was ascertained by record linkage to
the Israel National Cancer Registry (INCR). The INCR main-
tains records of all solid malignancies diagnosed since 1960,
and is updated annually according to mortality records.
Reporting to the registry has been mandated by law since
1982, and the data come from multiple sources: pathological
reports, hospital discharge medical files, oncology institutes,
and outpatient and private clinics. Completeness of reporting
reaches 95% for solid tumours [25].
Definitions of diabetesWe separately classified prevalent and
incident diabetes. Incident diabetes was defined as fulfilment
of at least one of the following six criteria after January 1,
2002: (1) case of diabetes included in the Clalit Chronic
Disease Registry; (2) a physician’s diagnosis of diabetes, to-
gether with one plasma glucose test >6.9 mmol/l within
12 months; (3) two plasma glucose measurements
>6.9 mmol/l within 12 months; (4) one measurement of
HbA1c ≥6.5%; (5) 2 h plasma glucose level during an oral
glucose tolerance test ≥11.1 mmol/l; and (6) three or more
purchases of glucose-lowering medication within 12 months.
The date of the earliest defining criterion was considered the
date of diabetes diagnosis. The prevalent diabetes group com-
prised patients who were recorded in the Clalit Chronic
Disease Registry as having diabetes on 1 January 2002 or
who fulfilled criterion no. 6 above (information on medication
use was available from 1998) before 1 January 2002.
The classification of diabetes used in the current study is
similar to that used by Clalit Health Services in a study of
diabetes incidence and prevalence that reported high internal
validity of the definition of diabetes [26].
Grading of prostate cancer Grading of prostate cancer was
according to the method defined by the Middle East Cancer
Consortium [27]. Well differentiated prostate cancers (i.e.
Gleason scores 2–4; Gleason patterns 1,2; histological grade I)
were coded 1; moderately differentiated prostate cancers (i.e.
Gleason scores 5,6; Gleason pattern 3; histological grade II)
were coded 2; and poorly differentiated prostate cancers (i.e.
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Gleason scores 7–10; Gleason patterns 4,5; histological grade
III) were coded 3.
Calculating HRs for prostate cancer among men with di-
abetes Preliminary analyses were performed to examine dis-
tributions of the main variables, check the plausibility of the
values reported and determine categories to be used in the
analysis. To estimate HRs for prostate cancer between those
with and without diabetes, Cox regression models were
applied, with adjustments for age (in 5 year age groups), eth-
nic origin (country of birth or mother’s country of birth:
Ashkenazi Jews [those born in Russia, Eastern Europe,
Europe, America or South Africa]; Sephardic Jews [those
born in mid and northern Africa or the Middle East];
Yemenite Jews; Ethiopian and Central African Jews; Israeli
Jews [including also Israeli-born Jews whose mothers’ birth-
places were unknown]; and Israeli Arabs) and socioeconomic
status (SES) according to affiliation to local Clalit Health
Services clinics (low, medium, high). Missing information
on SES was categorised as ‘missing’.
The time origin for the model was 1 January 2002. The HR
for individuals with prevalent diabetes (diagnosed before
2002) was estimated separately from that of those with inci-
dent diabetes. For incident diabetes, diabetes status (yes/no)
was included in the model as a time-dependent covariate. This
approach avoids the problem of immortal time bias that has
affected other research investigations of the relationship
between diabetes and cancer [28]. To account for potential
reverse causation, further time-dependent variables were
entered to distinguish between the first year, the second year
and the subsequent years following diabetes diagnosis. Men
who were not diagnosed with prostate cancer were censored at
the earliest of the following events: date of death, 90th birth-
day or 31 December 2012. When estimating the HR for pros-
tate cancer of a certain grade, all cases of prostate cancer with
a different grade were censored at the time of diagnosis.
An additional analysis was performed that also adjusted for
PSA screening. For this analysis, only follow-up years 2005–
2012 were considered, with adjustment for PSA screening
during 2002–2003. The rationale was that if PSA was tested
in 2002–2003, at least 2 years before prostate cancer ascer-
tainment, then the test was evidently indicated for screening
and not for diagnostic purposes. Onlymenwithout a diagnosis
of prostate cancer as of 1 January 2005 were included in this
analysis. Men who reached the age of 90 years or died before
1 January 2005 were excluded.
The analyses were performed using PROC PHREG of SAS
version 9.3 for PC (SAS Institute, Cary, NC, USA). We over-
came the problem of excessively long run-times that could occur
in the application of thismodel to amassive dataset, by grouping
events into 6 month periods and using the Breslow method for
handling tied event times [29]. This approach is similar to using
an exponential piecewise model with periods of 6 months.
Assessment of prostate cancer screening according to dia-
betes duration To investigate whether men with diabetes in
our study population underwent increased surveillance for
prostate cancer, we assessed the proportions of men aged
50 years and older who underwent PSA testing during a given
year (2008) according to the year of diabetes diagnosis (2003,
2007, 2008 and 2009) as well as of men who remained
diabetes-free during the study period 2002–2012. The years
of diabetes diagnosis were selected to depict PSA screening in
the period just before and just after diagnosis (2007, 2009), as
well as several years after (2003).
Comparison of PSAvalues between men with and without
diabetes To compare mean PSAvalues between men with and
without diabetes, before and after diagnosis, we examined for
each year during 2002–2012, mean PSA values of men diag-
nosed with diabetes in 2008 and of those not diagnosed with
diabetes by the end of 2008. To make the same comparison
over a longer period following the diagnosis of diabetes, we
examined mean PSA values during 2002–2012 in men diag-
nosed with diabetes before 2002 (prevalent diabetes group),
men diagnosed in 2002 and men not diagnosed by the end of
2012. Differences between groups were tested statistically
using mixed linear models applied to log-transformed PSA
values, adjusted for age.
Our investigations have been approved by the responsible
ethics committee (institutional review board) and were carried
out in accordance with the Declaration of Helsinki as revised
in 2008.
Results
Among the 1,034,074 men included, 765,483 (74%) remained
diabetes-free during the 11-year follow-up, 74,756 had preva-
lent diabetes and 193,835 incident diabetes (Table 1). A total of
14,099 prostate cancer events were registered in INCR during
that time. Among men diagnosed with prostate cancer, the pro-
portion of high Gleason scores (7–10) was greater for those
with than without diabetes, both for those with follow-up in
2002–2012 and the subgroup followed in 2005–2012
(Table 2). After adjusting for age, SES and ethnic origin, the
HR for all prostate cancer was 1.65 for men with incident dia-
betes (compared with men without diabetes) during the first
year following diabetes diagnosis (95% CI 1.55, 1.76); howev-
er, the HR decreased and was significantly lower than 1 by the
third and subsequent years following diabetes diagnosis (HR
0.89, 95% CI 0.84, 0.95), as it was for the prevalent diabetes
group (HR 0.80, 95% CI 0.76, 0.85; Table 3). An HR signifi-
cantly lower than 1 during the third and subsequent years fol-
lowing diagnosis was also observed for low-medium grade
prostate cancer (Gleason score 2–6; HR 0.83, 95% CI 0.77,
0.89); however, for high-grade cancer (Gleason score 7–10),
Diabetologia (2016) 59:1683–1691 1685
the estimated risk from the third year on after diagnosis was
hardly different from that of men without diabetes, with HR
0.99 (95% CI 0.88, 1.11; Table 3). The results of the sub-
analysis that controlled for PSA testing during 2002–2003were
similar to those for the full period analysis (Table 3).
Among men with incident diabetes aged 50 years and older,
PSA screening percentages in 2008 were 33.8% for those diag-
nosed 5 years earlier (2003), 35.1% for those diagnosed in the
previous year (2007), 42.4% for those diagnosed with diabetes
in the same year (2008) and 33.0% for those diagnosed the year
after (2009). By contrast, for men not diagnosed with diabetes
during the study period, 30.6% were screened for PSA in 2008
(Fig. 1). Thus, among men diagnosed with diabetes several
years earlier, the proportion screened in 2008 (33.8%) was
10% higher than among those who were not diagnosed with
diabetes during the study (30.6%). Adjusting for age, SES and
ethnic origin in a regression model did not change this finding
(not shown).
Mean PSA values were significantly lower for men with
diabetes, even prior to diabetes diagnosis (e.g. 2005 in Fig. 2).
Table 1 Characteristics of the
study population of men aged 21–








Age (years), mean ± SD 41.6 ± 15.9 62.6 ± 12.8 56.1 ± 14.5
Ethnic origina (%)
Ashkenazi Jews 27.05 33.13 31.74
Sephardic Jews 25.47 29.38 27.94
Israeli Jews 24.45 16.80 18.23
Israeli Arabs 19.12 14.95 16.70
Yemenite Jews 2.54 4.93 4.01
Ethiopian and Central African Jews 1.37 0.81 1.38
SES (%)
Low 40.57 40.85 42.31
Medium 38.24 39.82 37.91
High 17.43 16.54 17.00
Missing 3.77 2.78 2.78
Smoking (%)
Never smoker +missing 57.73 58.87 49.48
Past + current smoker 42.27 41.13 50.52
a According to country of birth or mother’s country of birth

















Person-years 9,002,033 640,388 982,263 6,268,686 431,200 876,460
Prostate cancer frequency, n
(crude rate per annum×103)
9,714 (1.08) 1,672 (2.61) 2,713 (2.76) 6,939 (1.11) 1,113 (2.58) 2,283 (2.60)
Gleason score for prostate cancer; n (%)
2, 3, 4 (1a) 177 (1.8) 33 (2.0) 31 (1.1) 81 (1.2) 14 (1.3) 15 (0.7)
5, 6 (2a) 5,983 (61.6) 852 (51.0) 1,567 (57.8) 4,666 (67.2) 623 (56.0) 1,375 (60.2)
7–10 (3a) 1,742 (17.9) 358 (21.4) 623 (23.0) 1,319 (19.0) 269 (24.2) 539 (23.6)
Unknown 1,812 (18.7) 429 (25.6) 492 (18.1) 873 (12.6) 207 (18.6) 354 (15.5)
PSA screening in 2002–2003
No PSA screening 677,412 (90.7) 47,025 (72.4) 144,003 (77.5)
PSA screen in 1 out of 2 years 50,505 (6.8) 12,990 (20.0) 29,671 (16.0)
PSA screen in 2 out of 2 years 18,634 (2.5) 4,986 (7.7) 12,214 (6.6)
a 1, 2, 3: According to Middle East Cancer Consortium manual of coding and staging [27]
1686 Diabetologia (2016) 59:1683–1691
Moreover, although mean values increased over time as indi-
viduals aged, they increased more rapidly among men without
diabetes than among men with diabetes (Figs 2, 3). For men
diagnosed with diabetes 10 years previously, mean PSA
values were similar to those of men with long-term diabetes
(the prevalent diabetes group; Fig. 3), and for both were ap-
proximately 20% lower than in men who were diabetes-free.
Over the period 2002–2012, the proportion of men with pos-
itive PSA values (above 4 μg/l) was 16–18% among those
diagnosed with diabetes in 2002, 13–18% among those with
prevalent diabetes and 17–23% in men free of diabetes.
Among men with incident diabetes, compared with men
who remained diabetes-free, the proportion with positive
PSA tests was 8% lower (ratio 0.92) in the year they were
diagnosed (2002) and decreased to about 20% lower (ratio
∼0.80) at about 6–8 years after diagnosis, thus reaching the
same ratio as for men with prevalent diabetes (Table 4).
Discussion
The main findings of this study were as follows: (1) in the
third and subsequent years following diabetes diagnosis, the
HR for prostate cancer was significantly less than 1 for low–
moderate grade prostate cancer (HR 0.83, 95% CI 0.77, 0.89)
but not for high-grade prostate cancer (HR 0.99, 95% CI 0.88,
1.11); (2) an approximately 10% higher PSA screening rate
was found among men with diabetes; (3) men who developed
diabetes had lower PSA levels prior to a diagnosis of diabetes,
with the gap widening during the first 10 years following
diagnosis; and (4) an approximately 20% lower rate of PSA
positivity (>4 μg/l) was found in men with diabetes from 6–8
years after diagnosis onwards. Other factors being equal, the
increased rate of screening among men with diabetes would
Table 3 Number of prostate cancers (NC), HRs and 95% CIs for HR for prostate cancer incidence in diabetic compared with non-diabetic men





14,099 prostate cancer events including
those in non-diabetics
Follow-up: 2005–2012a
PSA-adjustedb HR (95% CI)












1st year 2nd year 3rd year+ First 10 years 1st year 2nd year 3rd year+ First 7 years
All:
NC 767 354 1, 592 1, 672 460 276 1, 547 1, 113
HR 1.65 0.93 0.89 0.97 0.80 1.48 0.94 0.89 0.98 0.77
(95% CI) (1.55, 1.76) (0.84, 1.03) (0.84, 0.95) (0.93, 1.02) (0.76, 0.85) (1.37, 1.61) (0.83, 1.06) (0.84, 0.94) (0.94, 1.02) (0.72, 0.82)
2–6:
NC 420 217 961 885 271 179 940 637
HR 1.47 0.89 0.83 0.90 0.71 1.32 0.90 0.82 0.91 0.68
(95% CI) (1.35, 1.60) (0.77, 1.01) (0.77, 0.89) (0.85, 0.95) (0.66, 0.76) (1.19, 1.47) (0.78, 1.05) (0.77, 0.89) (0.85, 0.96) (0.62, 0.74)
7–10:
NC 180 66 377 358 119 51 369 269
HR 2.09 0.86 0.99 1.08 0.92 2.05 0.88 1.00 1.13 0.93
(95% CI) (1.83, 2.38) (0.66, 1.10) (0.88, 1.11) (0.98, 1.20) (0.82, 1.03) (1.75, 2.39) (0.67, 1.17) (0.89, 1.13) (1.02, 1.25) (0.82, 1.06)
Unknown:
NC 167 71 254 429 70 46 238 207
HR 1.78 1.18 1.09 1.17 0.98 1.51 1.21 1.08 1.16 0.96
(95% CI) (1.56, 2.03) (0.94, 1.48) (0.94, 1.26) (1.03, 1.31) (0.88, 1.09) (1.23, 1.86) (0.92, 1.61) (0.93, 1.25) (1.01, 1.30) (0.82, 1.12)
a Adjusted for age category (5 year increments), SES and ethnic origin
bAdjusted for PSA screening during 2002–2003
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Fig. 1 Percentage of PSA testing and 95% CI in 2008 in men with
diabetes aged ≥50 years, according to year of diabetes incidence, adjusted
for age, SES and ethnic group. The dashed line shows the 30.6% figure
for PSA screening in 2008 for men not diagnosedwith diabetes during the
study period
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be expected to result in an HR >1 for screening-detected
cancers. However, together with the lower PSA positivity,
an HR <1 would be expected. In fact, one would expect
an overall HR for prostate cancer of approximately
0.8 × 1.1 = 0.88 among men with diabetes, similar to the
observed results.
Lower androgen levels have been suggested as an explana-
tion for lower PSA levels in men with diabetes [30].
Testosterone has been shown to be positively associated with
PSA levels [31], and men with type 2 diabetes are known to
have lower testosterone levels [32].
The finding of lower PSA levels among men with diabe-
tes supports later detection, as well as a lower probability of
biopsy performance, as plausible explanations for lower
incidence rates of prostate cancer in men with diabetes.
These explanations are supported by our observation that
the inverse association was found only for low–moderate
grade tumours, and not for high-grade tumours. Assuming
that the PSA-level threshold for referral for biopsy is the
same for men with and without diabetes, then men with
diabetes would presumably be less likely to be referred
for biopsies than men without diabetes, for the same poten-
tial tumour severity. Among men with low-grade tumours,
fewer men with diabetes would be expected to be referred
for biopsy; yet, no such difference would be expected be-
tween men with and without diabetes for high-grade tu-
mours. In the REDUCE trial, in which all participants












2005 2006 2007 2008 2009 2010 2011 2012
1,576 1,997 2,255 2,501 2668 4,494 3,630 3,854 3,947 3,935
Diabetes-free 37,199 40,351 49,339 56,147 63,251 75,252 85,151 90,562 98,007 102,915 102,965
p value
comparing curves





1.75Fig. 2 Geometric mean PSA
levels by calendar year for men
aged 50–70 years in 2008, who
were diagnosed with diabetes in
the year 2008 (solid line) and men
free of diabetes at the end of 2008
(dashed line), adjusted to data for
a 60-year-old man. The number of
observations in each year is
shown below the graph; NS, not










2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
42,557 49,951 54,578 59,112
Follow-up (calendar year)
Year of diagnosis
67,459 74,330 76,419 80,547 82,751 81,461
Dx in 2002 5,515 4,592 5,395 5,598 5,890 6,498 7,044 6,883 7,267 7,465 7,010







Fig. 3 Geometric mean PSA
levels by calendar year for men
aged 50–70 years in 2002 who
were tested for PSA, according to
diabetes status in 2002, adjusted
to data for a 60-year-old man.
Solid line, diabetic men
diagnosed before 2002, dashed
line, diabetic men diagnosed in
2002; dotted line, men not
diagnosed with diabetes during
2002–2012. The number of
observations in each year is
shown below the graph. The
curves of the diabetic groups are
significantly different from the
curve of the non-diabetic group at
each time point (p< 0.001). Dx,
diagnosis
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regardless of PSA concentrations, diabetes was not associ-
ated with prostate cancer risk [33]. Other studies that com-
pared biopsies of men with and without diabetes reported
higher grade tumours for the former group [34]. The impli-
cation is that different interpretations of PSA levels may be
relevant to men with diabetes.
Similar to the findings and implications presented herein, a
lower PSA concentration in obese men has been suggested as
an explanation for delayed tumour detection, resulting in more
aggressive disease at presentation [22, 35]. Furthermore, obesi-
ty was found to be a risk factor for prostate cancer at the time of
biopsy, after adjusting for PSA levels and other clinical charac-
teristics [36]. Lower PSA levels among overweight and obese
men were shown to result in fewer biopsies [37]. Nevertheless,
a sensitivity analysis on data from 2009 to 2012 that adjusted
for BMI showed only modest, insubstantial changes in HRs of
diabetes vs no diabetes for prostate cancer [7].
Differences in secondary prevention practices across geo-
graphical regions may explain some of the discrepancies ob-
served among studies of diabetes and prostate cancer. In our
population, the increased PSA surveillance among men with
diabetes was dominated by the reduction in PSA positivity.
However, the impact of PSA screening on the detection rate of
prostate cancer among men with diabetes may differ accord-
ing to regional and temporal trends in screening practice. High
rates of prostate screening in the USA during the past 1–2
decades [37] may be related to the large number of US studies
that reported an increased protective effect on prostate cancer
with longer diabetes duration [7–9]. By contrast, diabetes du-
ration was reported to be associated with an increased risk of
prostate cancer in Taiwan [13]. Prostate screening in Taiwan
was found to be more than twofold higher among men with
than without diabetes. However, since the screening rate did
not exceed 1%, a great effect of screening on incidence rates
would not be expected. The rates of PSA screening in Israel,
reported in this study, are similar to those in the USA [38].
Recently published data show that prostate cancer screening,
as well as prostate cancer incidence, decreased following pub-
lication of the 2012 US Preventive Services Task Force
Recommendations [39, 40]. Yet to be determined is whether
this trend affects the association between diabetes and prostate
cancer incidence, as changes may have occurred in the pro-
portions of men with and without diabetes who are screened.
Moreover, owing to the indolent nature of prostate cancer, it
will take several years to verify the effect of current screening
trends on prostate cancer mortality and on differences in rates
between men with and without diabetes.
This was a population study, eliminating the problem of
selection bias. Reverse causation was addressed by calculating
HRs for prostate cancer among men with incident diabetes
separately for the first and second years, and for the third year
and after. The internal validity of this study was high, owing to
the uniformity and standardised treatment in Israeli healthcare,
especially in a single and the largest health maintenance orga-
nisation. There was no loss to follow-up and a relatively low
frequency of missing data in the main studied variables.
In this analysis, we did not investigate the role of glycaemic
control. Poor glycaemic control in men with type 1 diabetes
was recently reported to be associated with lower PSA levels,
independent of age, BMI, androgen levels, medication use and
measures of diabetes severity [41]. In men with type 2 diabe-
tes, poor glycaemic control has been found to be associated
with a higher risk of prostate cancer detection [42] and with
more aggressive prostate tumours [43]. Another limitation to
the current study is that the proportion of prostate biopsies
with undetermined Gleason grading reached 18–26%. In
Table 4 Numbers and percent-
ages of screened men aged 50–70
years with PSA test values >4 μg/
l according to year of test and di-
abetes status
Year Diabetes-free during follow-up Diabetes diagnosed in 2002 Prevalent diabetes:
diagnosed before 2002
na %PSA >4 μg/l na %PSA >4 μg/lb na %PSA >4 μg/lb
2002 39,860 17.2 5,515 15.9 (0.92) 11,217 12.6 (0.73)
2003 42,357 18.5 4,592 16.7 (0.90) 11,367 15.0 (0.81)
2004 49,951 18.3 5,395 16.8 (0.92) 12,718 15.2 (0.83)
2005 54,578 17.4 5,598 15.4 (0.89) 13,587 14.0 (0.80)
2006 59,112 19.1 5,890 16.9 (0.88) 14,246 15.7 (0.82)
2007 67,459 19.2 6,498 17.3 (0.90) 15,420 15.1 (0.79)
2008 74,330 19.8 7,044 15.9 (0.80) 16,726 16.1 (0.81)
2009 76,419 21.2 6,883 17.4 (0.82) 16,347 17.7 (0.83)
2010 80,547 21.2 7,267 18.3 (0.86) 16,584 17.0 (0.80)
2011 82,751 21.9 7,465 17.6 (0.80) 16,565 17.2 (0.79)
2012 81,461 22.6 7,010 18.3 (0.81) 16,710 17.6 (0.78)
a Numbers with a PSA test
b In parentheses, ratio of %PSA >4 μg/l to that in men without diabetes
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addition, we could not distinguish between non-smokers and
men with missing smoking information in our database. We
presume that such missing data would be more likely for non-
or light-smokers. Nevertheless, a pooled analysis of 24 pro-
spective cohort studies with over 21,579 prostate cancer cases
found no association between smoking and prostate cancer
incidence [44]. An effect of physical activity was not exam-
ined, as relevant data were not available in the database. No
information on type of diabetes was available, but using age as
a proxy for type 1 diabetes, the proportion of men younger
than 35 years at diabetes incidence or at study entry was very
low (3.1% and 2.3%, respectively) and no prostate cancer
events occurred among these men.
Data on prostate cancer stage and fatality were lacking due
to the absence of data on cause of death. Nonetheless, cause of
death data is not always reliable [45]. Moreover, death follow-
ing prostate cancer is dependent on age, comorbid conditions
and length of follow-up. Since diabetes is one of the comorbid
conditions to be considered, an assessment of death following
prostate cancer diagnosis would be biased. Thus, high
Gleason grade, as applied in this study, may be the most ap-
propriate way to assess prostate cancer severity.
The relationship between diabetes, prostate cancer screen-
ing and incidence of prostate cancer is complex, and may
differ across populations. Personalised screening strategies
that are tailored to men’s individual risks and preferences have
been advocated [46]. The findings of our current work suggest
that diabetes comorbidity is a factor to be considered in pros-
tate cancer screening strategies, and specifically in the inter-
pretation of PSA levels. Furthermore, our demonstration of
reduced incidence of low–moderate grade but not high-grade
prostate cancer among men with diabetes supports the possi-
bility that low PSA levels, rather than lower tumour risk, may
explain the observed reduced incidence of prostate cancer.
Prospective investigations are needed that assess PSA testing
and concentrations, as well as biopsy performance and find-
ings, in men with and without diabetes, in populations with
different screening practices.
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